Relationship Between Fremanezumab Exposure and Efficacy in Preventive Therapy of Episodic Migraine in Adults

Conference: AHS
Division: Cognigen


  • Fremanezumab is a fully humanized IgG2Δa/kappa monoclonal antibody that selectively targets calcitonin
    gene-related peptide (CGRP).1
  • Previously, fremanezumab was found to be effective and well-tolerated as a preventive treatment for migraine in
    3-month Phase 2 and 3 episodic and chronic migraine studies.2,3,4,5
  • Modeling and simulation were used to support dose selection for fremanezumab in patients with episodic migraine

    • An exposure-efficacy response model was developed to describe the relationship between fremanezumab
      exposure and the reduction in the monthly number of migraine days in patients with EM.
    • Simulations were performed to predict fremanezumab efficacy over 3 months, including the percent of patients
      with at least a 50% reduction from baseline in the number of migraine days at each month and as an average
      over 3 months.

Presented at American Headache Society 60 the Annual Scientific Meeting, June 28-July 1, 2018, San Francisco, CA, USA

By Jill Fiedler-Kelly, Julie A Passarell, Elizabeth A Ludwig